



Gland Pharma Limited

CIN: L24239TG19781PLC002276

Registered office: Survey No. 143-148, 150 & 151, Near Gandimaisamma 'X' Roads,
D.P. Pally, Dundigal-Gandimaisamma Mandal, Medchal-Malkajgiri District,
Hyderabad 500 043, Telangana, India

Telephone: +91-40-30510999; **Fax:** +91-40- 30510800

E-mail: gland@glandpharma.com; **Website:** www.glandpharma.com

ADDENDUM TO THE EXPLANATORY STATEMENT TO THE NOTICE OF THE 45th ANNUAL GENERAL MEETING

Date: August 25, 2023

Dear

DP ID Client ID. /Folio Number:

We hope that you and your family are safe and in good health!

This is with regard to the Item No. 5 of the Notice to the 45th Annual General Meeting of the Company dated August 1, 2023. Please find below the **Addendum to Item No. 5 to the details of the Statutory Auditors to be appointed (page No. 6 of 13 in the Notice to the 45th AGM).**

The below mentioned para should be included **after para 1** under Item No.5 : **To appoint M/s. Deloitte Haskins & Sells, Chartered Accountants (Firm's Registration No. 008072S) as Statutory Auditors of the Company and fix their remuneration:**

"The proposed remuneration to be paid to Deloitte Haskins & Sells for audit services for the financial year ending March 31, 2024, is INR 11.2 Mn (Rupees Eleven Million and Two Hundred Thousand only) plus applicable taxes and out-of-pocket expenses. The said fees will be appropriately adjusted for any significant changes in the scope of the statutory audit, significant business development, etc.

Besides the audit services, the Company would also obtain certifications from the statutory auditors under various statutory regulations and certifications required by clients, banks, statutory authorities, audit related services and other permissible non-audit services as required from time to time, for which they will be remunerated separately on mutually agreed terms, as approved by the Board of Directors in consultation with the Audit Committee. The above fee excludes the proposed remuneration to be paid to overseas audit firms for the purpose of statutory audit of overseas subsidiaries and branches. The Board of Directors and the Audit Committee shall approve revisions to the remuneration of the statutory auditors for the remaining part of the tenure.



The Board of Directors, in consultation with the Audit Committee, may alter and vary the terms and conditions of appointment, including remuneration, in such manner and to such extent as may be mutually agreed with the statutory auditors.

There is no material change in the remuneration proposed to be paid to Auditors for the financial year 2023-24 and the remuneration paid to the Retiring Auditors (S.R.Batliboi & Associates L.L.P) for the financial year 2022-23”.

Thank you and looking forward to your presence at the AGM.

Regards,

For Gland Pharma Limited

Sd/-

Sampath Kumar Pallerlamudi

Company Secretary

(Membership No.: A17901)